Terms: = Lymphoma AND FGFR3, CD333, 2261, ENSG00000068078, P22607, JTK4, ACH, HSFGFR3EX, CEK2
76 results:
1. Clinicopathological and genetic landscape of plasmablastic lymphoma in Taiwan.
Chen BJ; Hsieh TH; Yuan CT; Wang RC; Yang CF; Chuang WY; Su YZ; Ho CH; Lin CH; Chuang SS
Pathol Res Pract; 2024 Jan; 253():155059. PubMed ID: 38160484
[TBL] [Abstract] [Full Text] [Related]
2. DNA Copy Number Alterations and Copy Neutral Loss of Heterozygosity in Adult Ph-Negative Acute B-Lymphoblastic Leukemia: Focus on the Genes Involved.
Risinskaya N; Gladysheva M; Abdulpatakhov A; Chabaeva Y; Surimova V; Aleshina O; Yushkova A; Dubova O; Kapranov N; Galtseva I; Kulikov S; Obukhova T; Sudarikov A; Parovichnikova E
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139431
[TBL] [Abstract] [Full Text] [Related]
3. Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung.
Alidousty C; Becker A; Binot E; Hillmer AM; Merkelbach-Bruse S; Budde B; Bäßmann I; Rappl G; Wolf J; Eich ML; Noh KW; Buettner R; Schultheis AM
Gene; 2024 Feb; 895():148018. PubMed ID: 37981082
[TBL] [Abstract] [Full Text] [Related]
4. Detection of clinically actionable gene fusions by next-generation sequencing-based RNA sequencing of non-small cell lung cancer cytology specimens: A single-center experience with comparison to fluorescence in situ hybridization.
Diks J; Tang Z; Altan M; Anderson S; Chen H; Rashid A; Yang RK; Routbort MJ; Patel KP; Toruner GA; Medeiros LJ; Tang G; Luthra R; Roy-Chowdhuri S
Cancer Cytopathol; 2024 Jan; 132(1):41-49. PubMed ID: 37747438
[TBL] [Abstract] [Full Text] [Related]
5. Guilingji capsule for Alzheimer's disease: secondary analysis of a randomized non-inferiority controlled trial.
Ming Z; Yimiao L; Huichan W; Yu C; Lina MA; Hui P; Hao LI
J Tradit Chin Med; 2023 Oct; 43(5):1019-1025. PubMed ID: 37679990
[TBL] [Abstract] [Full Text] [Related]
6. Unraveling the Mystery: Next Generation Sequencing Sheds Light on Neuroblastoma Pathogenesis and Targeted Therapies.
Aktas T; Kızmazoglu D; Aktas S; Erol A; Serinan E; Gokbayrak O; Ozdemir SM; Altun Z; Ozer E; Cecen E; Ince D; Olgun N
Front Biosci (Landmark Ed); 2023 Aug; 28(8):171. PubMed ID: 37664946
[TBL] [Abstract] [Full Text] [Related]
7. Fibroblast growth factor receptor 3 overexpression mediates ALK inhibitor resistance in ALK-rearranged non-small cell lung cancer.
Sakashita T; Yanagitani N; Koike S; Low SK; Takagi S; Baba S; Takeuchi K; Nishio M; Fujita N; Katayama R
Cancer Sci; 2022 Nov; 113(11):3888-3900. PubMed ID: 35950895
[TBL] [Abstract] [Full Text] [Related]
8. Clonal germinal center B cells function as a niche for T-cell lymphoma.
Fujisawa M; Nguyen TB; Abe Y; Suehara Y; Fukumoto K; Suma S; Makishima K; Kaneko C; Nguyen YTM; Usuki K; Narita K; Matsue K; Nakamura N; Ishikawa S; Miura F; Ito T; Suzuki A; Suzuki Y; Mizuno S; Takahashi S; Chiba S; Sakata-Yanagimoto M
Blood; 2022 Nov; 140(18):1937-1950. PubMed ID: 35921527
[TBL] [Abstract] [Full Text] [Related]
9. Genetic correlation of crizotinib efficacy and resistance in ALK- rearranged non-small-cell lung cancer.
Liu C; Liu C; Liao J; Yin JC; Wu X; Zhao X; Sun S; Wang H; Hu Z; Zhang Y; Yu H; Shao Y; Wang J
Lung Cancer; 2022 Sep; 171():18-25. PubMed ID: 35870258
[TBL] [Abstract] [Full Text] [Related]
10. Germline CHEK2 and ATM Variants in Myeloid and Other Hematopoietic Malignancies.
Stubbins RJ; Korotev S; Godley LA
Curr Hematol Malig Rep; 2022 Aug; 17(4):94-104. PubMed ID: 35674998
[TBL] [Abstract] [Full Text] [Related]
11. Plasmablastic myeloma in Taiwan frequently presents with extramedullary and extranodal mass mimicking plasmablastic lymphoma.
Chen BJ; Yuan CT; Yang CF; Ho CH; Lin YK; Su YZ; Chou HC; Chuang SS
Virchows Arch; 2022 Aug; 481(2):283-293. PubMed ID: 35657404
[TBL] [Abstract] [Full Text] [Related]
12. Presentation and Impact of Double and Triple hit Cytogenetics in Patients With Multiple Myeloma in the Real World.
Singh C; Panakkal V; Sreedharanunni S; Jandial A; Jain A; Lad D; Prakash G; Khadwal A; Malhotra P
Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):e685-e690. PubMed ID: 35422411
[TBL] [Abstract] [Full Text] [Related]
13. Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes.
Yao Y; Yu Z; Ma Y; Ou Q; Wu X; Lu D; Li X
ESMO Open; 2022 Apr; 7(2):100405. PubMed ID: 35305401
[TBL] [Abstract] [Full Text] [Related]
14. Clinical characteristics and survival outcomes of newly diagnosed multiple myeloma patients presenting with extramedullary disease: A retrospective study.
Gao S; Li Q; Dong F; Yang P; Chen Y; Wang J; Wang Y; Jing H
Leuk Res; 2022 Apr; 115():106793. PubMed ID: 35248783
[TBL] [Abstract] [Full Text] [Related]
15. Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study.
Kim J; Gianferante M; Karyadi DM; Hartley SW; Frone MN; Luo W; Robison LL; Armstrong GT; Bhatia S; Dean M; Yeager M; Zhu B; Song L; Sampson JN; Yasui Y; Leisenring WM; Brodie SA; de Andrade KC; Fortes FP; Goldstein AM; Khincha PP; Machiela MJ; McMaster ML; Nickerson ML; Oba L; Pemov A; Pinheiro M; Rotunno M; Santiago K; Wegman-Ostrosky T; Diver WR; Teras L; Freedman ND; Hicks BD; Zhu B; Wang M; Jones K; Hutchinson AA; Dagnall C; Savage SA; Tucker MA; Chanock SJ; Morton LM; Stewart DR; Mirabello L
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 34308104
[TBL] [Abstract] [Full Text] [Related]
16. NGS-based liquid biopsy profiling identifies mechanisms of resistance to ALK inhibitors: a step toward personalized NSCLC treatment.
Sánchez-Herrero E; Serna-Blasco R; Ivanchuk V; García-Campelo R; Dómine Gómez M; Sánchez JM; Massutí B; Reguart N; Camps C; Sanz-Moreno S; Calabuig-Fariñas S; Jantus-Lewintre E; Arnal M; Fernández-Orth D; Calvo V; González-Rumayor V; Provencio M; Romero A
Mol Oncol; 2021 Sep; 15(9):2363-2376. PubMed ID: 34058070
[TBL] [Abstract] [Full Text] [Related]
17. Shorter Diagnosis-to-Treatment Interval in Diffuse Large B-Cell lymphoma is Associated With Inferior Overall Survival in a Large, Population-Based Registry.
Blunt DN; Smyth L; Nagamuthu C; Gatov E; Croxford R; Mozessohn L; Cheung MC
J Natl Compr Canc Netw; 2021 Mar; 19(6):719-725. PubMed ID: 33691276
[TBL] [Abstract] [Full Text] [Related]
18. PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial.
Borchmann P; Plütschow A; Kobe C; Greil R; Meissner J; Topp MS; Ostermann H; Dierlamm J; Mohm J; Thiemer J; Sökler M; Kerkhoff A; Ahlborn M; Halbsguth TV; Martin S; Keller U; Balabanov S; Pabst T; Vogelhuber M; Hüttmann A; Wilhelm M; Zijlstra JM; Moccia A; Kuhnert G; Bröckelmann PJ; von Tresckow B; Fuchs M; Klimm B; Rosenwald A; Eich H; Baues C; Marnitz S; Hallek M; Diehl V; Dietlein M; Engert A
Lancet Oncol; 2021 Feb; 22(2):223-234. PubMed ID: 33539742
[TBL] [Abstract] [Full Text] [Related]
19. Erdafitinib as a Novel and Advanced Treatment Strategy of Metastatic Urothelial Carcinoma.
Bansal P; Dwivedi DK; Hatwal D; Sharma P; Gupta V; Goyal S; Maithani M
Anticancer Agents Med Chem; 2021; 21(18):2478-2486. PubMed ID: 33475078
[TBL] [Abstract] [Full Text] [Related]
20. Identification and Characterization of Copy Number-Associated Driver Genes in Esophageal Squamous Cell Carcinoma.
Jiang K; He Y; Zhang X
Biomed Res Int; 2020; 2020():6387519. PubMed ID: 32908901
[TBL] [Abstract] [Full Text] [Related]
[Next]
